Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Files An 8-K Regulation FD DisclosureItem 7.01Regulation FD.
On September14, 2017, Alder BioPharmaceuticals, Inc. will provide to certain of its stockholders and securities analysts a written update regarding recent presentations and feedback from the 18th Congress of the International Headache Society. A copy of the communication is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
The information in this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 7.01 Financial Statements and Exhibits.
(d) Exhibits.
ALDER BIOPHARMACEUTICALS INC ExhibitEX-99.1 2 d458610dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 ALDER’S NOTES FROM THE ROAD September 14,…To view the full exhibit click here
About Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company’s pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Company’s monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone, and is being developed for the treatment of Cushing’s disease. Its candidate, Eptinezumab, is an investigational product candidate being developed as a migraine prevention treatment for patients with chronic and frequent episodic migraine. It is also is developing ALD1910, a genetically engineered monoclonal antibody.
